CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (NASDAQ:COTQF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “

Separately, ValuEngine lowered CRITICAL OUTCOME T COM NPV(POST REV SPLIT) from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 28th.

Shares of CRITICAL OUTCOME T COM NP (COTQF) traded up 4.4551% on Friday, reaching $0.8511. 500 shares of the company were exchanged. The firm’s market capitalization is $13.79 million. The stock’s 50-day moving average is $0.25 and its 200 day moving average is $0.22. CRITICAL OUTCOME T COM NP has a 12-month low of $0.83 and a 12-month high of $4.80.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/06/critical-outcome-t-com-npvpost-rev-split-cotqf-lowered-to-sell-at-zacks-investment-research.html.

CRITICAL OUTCOME T COM NPV(POST REV SPLIT) Company Profile

Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The company’s proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.

Receive News & Stock Ratings for CRITICAL OUTCOME T COM NPV(POST REV SPLIT) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRITICAL OUTCOME T COM NPV(POST REV SPLIT) and related stocks with our FREE daily email newsletter.